iSchemaView Technology RAPIDly Adopted by Over 350 Stroke Centers

Share Article

RAPID becoming a new standard in advanced cerebrovascular imaging

Rapid logo

RAPID

Now there's the potential to treat based on best evidence not just best guess, that’s what RAPID’s perfusion platform affords. — Christian Ramsey, MD, Neurosurgeon and Surgical Director of Stroke at Baptist Health System.

iSchemaView, the leader in cerebrovascular imaging analysis, today announced accelerating adoption of its platform. As of today over 350 stroke centers are now using RAPID advanced imaging technology to assist physicians in the analysis of brain images using automated tools for CT, CT Perfusion, MR diffusion and perfusion.

With over 350 stroke centers now using RAPID around the world, regular daily use at the centers is generating over 50,000 scans a year. With 200 or more systems expected to come online in 2018, scan count is projected to approach 100,000 per year.

“It is terrific to see the industry respond so dramatically to recent studies and adopt RAPID so quickly,” said Don Listwin, CEO of iSchemaView. “The most important result is that we are getting our complete imaging solution into as many hospitals as possible for the benefit of substantially more addressable patients. We want to put an end to time constrained ‘wait and see’ stroke outcomes, and put RAPID to work for all.”

Under IRB approval, iSchemaView’s RAPID platform was recently used to select patients for two landmark stroke trials published in The New England Journal of Medicine, DAWN and DEFUSE 3, that successfully treated patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The results of the studies helped change the AHA stroke guidelines to include CT Perfusion and MR perfusion.

The prior treatment window for mechanical thrombectomy was up to six hours. Starting in 2018, select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well.

"Now there's the potential to treat based on best evidence not just best guess, that’s what RAPID’s perfusion platform affords,” said Christian Ramsey, MD, Neurosurgeon and Surgical Director of Stroke at Baptist Health System. “More patients with more treatment options offers the potential for successful outcomes in patients with historically terrible prognoses.”

Today, Gregory W. Albers MD, Stanford University Neurologist and cofounder of iSchemaView, will also be presenting Expanding the Time Window for Thrombectomy: Results of the DEFUSE 3 Study at the Annual Meeting of The American Academy of Neurology in Los Angeles.

About iSchemaView
iSchemaView is the leader in cerebrovascular imaging analysis, delivering the proven software tools that healthcare professionals around the world use to successfully identify and treat more stroke patients than ever before. iSchemaView’s RAPID is the most advanced brain imaging platform, and in clinical trials, under IRB, RAPID has been shown to aid in the selection of patients in early and late window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN and DEFUSE 3. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, these landmark studies led to new American Heart Association and American Stroke Association guidelines, and have dramatically altered the management of acute stroke around the world. For more information, visit http://www.iRAPID.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Eric Schubert
Natron Communications
+1 415-939-4366
Email >
Visit website